Guidant Returns to CRT-D Market With New Supplier For Problem Component
This article was originally published in The Gray Sheet
Executive Summary
Guidant expects to fully re-supply U.S. customers with Contak Renewal 3 cardiac resynchronization implantable defibrillators (CRT-D) by the end of August, following FDA approval to re-launch the device
You may also be interested in...
As J&J Backs Away From The Altar, Guidant Asks Court For Shotgun Wedding
Johnson & Johnson is likely to point to Guidant's weak third quarter sales and earnings as evidence that recent recalls have had a "material adverse effect" on Guidant
As J&J Backs Away From The Altar, Guidant Asks Court For Shotgun Wedding
Johnson & Johnson is likely to point to Guidant's weak third quarter sales and earnings as evidence that recent recalls have had a "material adverse effect" on Guidant
Guidant Issues Alert For Nine Pacemakers; Total Number Of Alerts Now 20
Guidant's most recent safety alert on certain pacemaker models is the first of the recent series of Guidant cardiac rhythm management device field actions to advise doctors to consider replacement